

STADA CIS is a member of STADA Arzneimittel AG Group, one of the world leading manufacturers of generics.

According to the results of 2014, STADA CIS has the second largest sales volume among STADA Arzneimittel AG markets. In 2014 the sales volume in Russia amounted to 360.7 mln. Euro.

As of today, the product portfolio includes more than 150 products of different ATC-classes and dosage forms which are manufactured by the leading Russian and international pharmaceutical companies – NIZHPHARM, STADA AG, Hemofarm A.D., Grünenthal etc.

STADA CIS focuses on the products of such socially significant fields, such as cardiology, neurology, gynecology, urology etc.

STADA CIS has a diversified organizational structure that comprises units specializing in three major fields: R&D, production and marketing.

- **STADA PharmDevelopment**, an R&D division of STADA CIS. On the basis of its own research laboratories it deals with development, scaling and release into the market of high-technological medicines, and takes an active part in the program of substitution of imported medicines by more affordable Russian equivalents. The specialists of the holding, in cooperation with leading R&D Russian and CIS centers, also carry out clinical research and development of innovative medicines in the most important therapeutic fields.
- The production sites of STADA CIS - **Nizhpharm** (Nizhny Novgorod) and **Hemofarm** (Obninsk) – are remarkable for one of the best quality management systems among the Russian pharmaceutical companies. All the production sites of the holding comply with international GMP standards. The quality management system and the environmental system are certified according to international standards ISO 9001:2008 and ISO 14001:2004.



- **STADA Marketing, STADA Ukraine, STADA Central Asia, STADA Baltia, STADA Azerbaidjan, STADA Armenia, STADA Belarus, STADA Georgia, STADA Moldova** are responsible for the implementation of the marketing policy aimed at the support of the most perspective products in the key pharmaceutical markets for STADA CIS – in Russia, Ukraine, Belarus, Moldova, Central Asia (Kazakhstan, Tajikistan, Kyrgyzstan, Uzbekistan), Transcaucasian countries (Georgia, Armenia, Azerbaijan) and the Baltic States (Latvia, Lithuania, Estonia).

STADA CIS follows the policy of concentrating the efforts on the development of modern unique medicines in the most important, socially significant medicine fields. It makes continuous investments into the quality management system and improvement of the production technology. STADA CIS strives for the achievement of the priority strategic goal – provision of the consumers with the high-quality, safe and effective medicines at affordable prices.